In the present study, the serum concentration of sST2 was associated with OS of HCC. Therefore, sST2 may be considered as a new prognostic marker in HCC and is worth further evaluation.

Sphingosine-1-phosphate (S1P) is an immune modulator produced by sphingosine kinase (SphK)1 and SphK2 and dephosphorylated by two S1P phosphatases or irreversibly degraded by a lyase. We recently showed that Toll-like receptor (TLR)4-induced IL-12p70 is selectively counter regulated by SphK1 and extracellular S1P/S1PR1. Others demonstrated that specific SphK1-dependent binding of intracellular S1P to TRAF2 enhances TNF signaling. In an ongoing investigation to determine the influence of extra- and intracellular S1P on dendritic cell signaling our experiments revealed that activation of TLR4 by lipopolysaccharide dose and time dependently decreased S1P lyase mRNA expression of murine bone marrow-derived dendritic cells by up to 70%. This set of realtime PCR data was further confirmed by semi-quantitative RT-PCR using exon-specific primers for murine sgpl1. Systematic analysis with dose-optimized ligands of TLRs 1/2, 5, 2/6, 7/8 and TLR9 showed a differential pattern of S1P lyase down regulation with concomitant increase of intracellular S1P. Although S1P lyase defcient mice are immune compromised, we found that TLR-induced transient S1P lyase downregulation resulted in a TLR adaptor-dependent upregulation of IL-12p70, IL-23 and IL-6 expression on mRNA and protein level. Further experiments including cell compartment-specific quantification of S1P, hexadecenal and, possibly counter regulatory, sphingolipid enzymes are necessary to understand the role of sphingolipids in DC.

BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor, usually arises in the setting of liver cirrhosis (LC), and has a poor prognosis. The recently discovered Th2-cytokine interleukin-33 (IL-33) is a possible mediator in pancreatic and gastric carcinogeneses. IL-33 binds to its receptor and to soluble ST2 (sST2), which thereby acts as a regulator. The role of IL-33 and sST2 in HCC has not been elucidated yet. METHODS: We conducted a case-control study with 130 patients and 50 healthy controls (HCs). Sixty-five patients suffered from HCC and 65 patients had LC without HCC. We assessed serum IL-33 and sST2 levels and their association with established prognostic scores, liver function parameters, and overall survival (OS). RESULTS: No significant difference in IL-33 serum levels was found in HCC compared to LC and HCs. IL-33 levels did not correlate with OS, liver function parameters, the Model for End-Stage Liver Disease (MELD) score, or the Cancer of the Liver Italian Program (CLIP) score. sST2 levels were significantly elevated in LC and HCC patients compared to HCs (P < .0001). Mean sST2 levels in LC were higher than in HCC (P < .0001), but a significant association with OS was only observed in the HCC group (P = .003). sST2 in HCC correlated with the CLIP score, the MELD score, and liver function parameters. CONCLUSION: In the present study, the serum concentration of sST2 was associated with OS of HCC. Therefore, sST2 may be considered as a new prognostic marker in HCC and is worth further evaluation.